Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHNASDAQ:OPCHNASDAQ:RDNTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$38.00+2.6%$43.39$20.14▼$52.92$4.71B1.492.16 million shs1.37 million shsOPCHOption Care Health$31.41-1.9%$32.99$21.39▼$35.53$5.14B0.761.86 million shs836,498 shsRDNTRadNet$56.61-0.3%$52.81$45.00▼$93.65$4.25B1.46686,135 shs454,156 shsVCYTVeracyte$27.16-0.9%$30.57$19.73▼$47.32$2.13B2.14892,894 shs612,390 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health+2.56%-6.57%-16.90%-11.36%+68.81%OPCHOption Care Health-1.94%-5.48%-2.28%-1.84%+8.20%RDNTRadNet-0.28%-7.41%+15.51%-4.81%-2.51%VCYTVeracyte-0.88%-6.99%-13.64%-30.68%+25.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHGuardant Health4.6364 of 5 stars4.52.00.04.34.02.50.6OPCHOption Care Health4.445 of 5 stars2.45.00.04.24.42.51.3RDNTRadNet3.4155 of 5 stars2.71.00.04.63.52.50.0VCYTVeracyte3.9411 of 5 stars4.41.00.04.33.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.05Buy$52.3237.68% UpsideOPCHOption Care Health 2.88Moderate Buy$35.5013.02% UpsideRDNTRadNet 3.40Buy$69.7523.21% UpsideVCYTVeracyte 2.70Moderate Buy$40.9050.59% UpsideCurrent Analyst Ratings BreakdownLatest VCYT, OPCH, GH, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/1/2025GHGuardant HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $65.005/1/2025GHGuardant HealthTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $60.005/1/2025GHGuardant HealthBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $60.005/1/2025GHGuardant HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $60.005/1/2025GHGuardant HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $70.004/30/2025OPCHOption Care HealthBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$38.00 ➝ $38.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$774.00M6.08N/AN/A$1.34 per share28.36OPCHOption Care Health$5.19B0.99$1.83 per share17.19$8.03 per share3.91RDNTRadNet$1.87B2.27$3.01 per share18.81$11.79 per share4.80VCYTVeracyte$463.39M4.59$0.06 per share442.29$14.30 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%8/6/2025 (Estimated)OPCHOption Care Health$267.09M$1.2426.3924.932.304.37%15.30%6.57%7/30/2025 (Estimated)RDNTRadNet$3.04M-$0.43N/A106.81N/A-0.25%4.29%1.45%8/5/2025 (Estimated)VCYTVeracyte-$74.40M$0.41N/A37.72N/A-2.18%3.02%2.80%8/5/2025 (Estimated)Latest VCYT, OPCH, GH, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million4/29/2025Q1 2025OPCHOption Care Health$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billion2/27/2025Q4 2024RDNTRadNet$0.21$0.22+$0.01$0.07$459.42 million$477.10 million2/24/2025Q4 2024VCYTVeracyte$0.29$0.36+$0.07$0.06$110.73 million$118.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AOPCHOption Care HealthN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A6.225.85OPCHOption Care Health0.771.731.32RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%OPCHOption Care Health98.05%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%OPCHOption Care Health0.64%RDNTRadNet5.12%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health1,790123.89 million116.76 millionNot OptionableOPCHOption Care Health5,600163.75 million169.09 millionOptionableRDNTRadNet8,97075.03 million70.24 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableVCYT, OPCH, GH, and RDNT HeadlinesRecent News About These CompaniesMan Group plc Sells 294,029 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 23 at 4:28 AM | marketbeat.comDeutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 23 at 3:34 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Nuveen Asset Management LLCMay 22 at 4:24 AM | marketbeat.comComparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)May 22 at 1:37 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Virtus Investment Advisers Inc.May 21 at 7:31 AM | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 21 at 4:03 AM | marketbeat.comVeracyte to Participate in Upcoming Investor ConferencesMay 20, 2025 | businesswire.comPoint72 Asset Management L.P. Buys Shares of 523,162 Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $7.61 Million Position in Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Bank of America Corp DEMay 20, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte Stock Surges 30.9% in a Year: What's Driving the Rally?May 19, 2025 | zacks.comLazard Asset Management LLC Boosts Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 19, 2025 | marketbeat.comResearch Analysts Set Expectations for Veracyte Q2 EarningsMay 18, 2025 | marketbeat.comWilliam Blair Predicts Veracyte's Q2 Earnings (NASDAQ:VCYT)May 18, 2025 | americanbankingnews.comParkman Healthcare Partners LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 16, 2025 | marketbeat.comHead to Head Contrast: Veracyte (NASDAQ:VCYT) & Grail (NASDAQ:GRAL)May 15, 2025 | americanbankingnews.comGranahan Investment Management LLC Has $1.96 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 13, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Fred Alger Management LLCMay 13, 2025 | marketbeat.comAxa S.A. Trims Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 11, 2025 | marketbeat.comNorthern Trust Corp Has $42.34 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT)May 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?NVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceTop 5 Stocks Hedge Funds Are Buying Right NowBy Ryan Hasson | May 20, 2025View Top 5 Stocks Hedge Funds Are Buying Right NowSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersVCYT, OPCH, GH, and RDNT Company DescriptionsGuardant Health NASDAQ:GH$38.00 +0.95 (+2.56%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$38.40 +0.40 (+1.05%) As of 05/23/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Option Care Health NASDAQ:OPCH$31.41 -0.62 (-1.94%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$31.00 -0.41 (-1.32%) As of 05/23/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.RadNet NASDAQ:RDNT$56.61 -0.16 (-0.28%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$57.78 +1.17 (+2.06%) As of 05/23/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$27.16 -0.24 (-0.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$27.14 -0.02 (-0.06%) As of 05/23/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
